2025
Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer
Westvold S, Long J, Fan J, Kc M, Hyslop T, Conlin K, Jacobson S, Silber A, Wang S, Leapman M, Leeds I, Spees L, Wheeler S, Gross C, Oeffinger K, Dinan M. Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. Journal Of The National Cancer Institute 2025, djaf243. PMID: 41069232, DOI: 10.1093/jnci/djaf243.Peer-Reviewed Original ResearchThis study investigates cardiovascular risk in older long-term cancer survivors, showing non-cancer factors, rather than cancer-specific ones, predict late-onset cardiovascular disease.Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications
Wheeler S, Rotter J, Spees L, Biddell C, Trogdon J, Alfano C, Mayer D, Dinan M, Nekhlyudov L, Birken S. Machine Learning Risk Stratification for Older Breast Cancer Survivors: Clinical Care Implications. Health Services Research 2025, e70005. PMID: 40671264, DOI: 10.1111/1475-6773.70005.Peer-Reviewed Original ResearchBreast cancer survivorsAdverse health outcomesCancer survivorsHealth outcomesCancer-specific deathOlder breast cancer survivorsClinical care implicationsRisk prediction algorithmsAdverse outcomesHigh riskSEER-CAHPSRisk of all-cause deathPrimary careSurvivorship outcomesClinical risk prediction algorithmsCare implicationsClaims dataAll-cause deathCohen's kappaEnd ResultsSurvivorsCancer recurrenceFollow-up periodLow riskCare
2023
Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer.
Westvold S, KC M, Fan J, Hyslop T, Spees L, Wang S, Silber A, Oeffinger K, Dinan M. Demographic and clinical factors associated with cardiovascular events in elderly long-term survivors of breast cancer. Journal Of Clinical Oncology 2023, 41: e24105-e24105. DOI: 10.1200/jco.2023.41.16_suppl.e24105.Peer-Reviewed Original ResearchLong-term breast cancer survivorsBreast cancer survivorsLong-term survivorsCardiovascular diseaseCancer survivorsHigh riskCancer stageRace/ethnicityClinical characteristicsDiagnosis yearBreast cancerEvidence of CVDNon-Hispanic black patientsNon-metastatic breast cancerLong-term cancer survivorsCox proportional hazards modelCurative-intent surgeryCVD hazard ratiosNon-oncologic outcomesCancer-specific survivalStage III diseaseInitial cancer diagnosisDiagnosis of CVDRace/ethnicity groupsChi-square test
2021
Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations
Miller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Vitamin D, Insulin-Like Growth Factor, and Cognitive Performance: Age and Sex Variations. Innovation In Aging 2021, 5: 703-703. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaProportional hazards regressionOral anticancer agentsMRCC diagnosisCell carcinomaHazards regressionRisk factorsCox proportional hazards regressionOlder adultsNon-cancer controlsMild cognitive impairmentCohort entryRenal dysfunctionOnly patientsSurgical therapyWhite patientsBlack patientsSEER-MedicareDementia onsetMAIN OUTCOMEExclusion criteriaHigh riskPatientsCognitive impairment
2020
Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).
Brander D, Oeffinger K, Greiner M, Dinan M. Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL). Journal Of Clinical Oncology 2020, 38: e24050-e24050. DOI: 10.1200/jco.2020.38.15_suppl.e24050.Peer-Reviewed Original ResearchDual-energy X-ray absorptiometryChronic lymphocytic leukemiaFragility fracturesCumulative incidenceBone mineral density screeningComplications of osteoporosisUse of bisphosphonatesRoutine health maintenanceX-ray absorptiometryWilcoxon rank sum testChi-square testRank sum testCumulative incidence functionBisphosphonate useBaseline characteristicsMedicare 5Adverse outcomesBMD screeningTreatment advancesGray's testChronic cancerMedicare patientsDXA useLymphocytic leukemiaHigh risk
2015
Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.
Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. Journal Of The National Comprehensive Cancer Network 2015, 13: e1-7. PMID: 25583775, DOI: 10.6004/jnccn.2015.0014.Peer-Reviewed Original ResearchConceptsFebrile neutropeniaHigh riskNCCN Clinical Practice GuidelinesBroad-spectrum antibiotic treatmentCommon dose-limiting toxicityChemotherapy dose reductionsConsideration of prophylaxisLow-risk regimensDose-limiting toxicityChemotherapy-induced neutropeniaClinical practice guidelinesHealth care useEpisode of careMyeloid growth factorsGrowth factor useEarly treatment terminationHealth care costsPrimary prophylaxisMyelosuppressive chemotherapySupportive careSerious morbidityTreatment delayTherapeutic optionsAntibiotic treatmentCare use
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply